Quantbot Technologies LP Invests $1.09 Million in Certara, Inc. (NASDAQ:CERT)

Quantbot Technologies LP bought a new position in shares of Certara, Inc. (NASDAQ:CERT) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 92,888 shares of the company’s stock, valued at approximately $1,088,000. Quantbot Technologies LP owned 0.06% of Certara at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CERT. Price T Rowe Associates Inc. MD increased its position in shares of Certara by 6.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 58,899 shares of the company’s stock valued at $1,054,000 after buying an additional 3,639 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Certara by 2.9% during the 1st quarter. Janus Henderson Group PLC now owns 127,399 shares of the company’s stock valued at $2,279,000 after acquiring an additional 3,578 shares in the last quarter. SG Americas Securities LLC acquired a new position in Certara during the second quarter worth about $226,000. Blue Trust Inc. purchased a new stake in shares of Certara in the second quarter valued at about $26,000. Finally, Louisiana State Employees Retirement System grew its position in shares of Certara by 2.3% in the second quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company’s stock valued at $751,000 after purchasing an additional 1,200 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Insider Buying and Selling

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Leif E. Pedersen sold 51,224 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at $1,125,658.16. This trade represents a 33.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Friday, September 27th. Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird decreased their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.92.

Certara Price Performance

CERT opened at $11.21 on Friday. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a fifty day simple moving average of $10.81 and a 200 day simple moving average of $13.00. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of -56.05, a PEG ratio of 5.70 and a beta of 1.51. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm’s revenue was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.06 EPS. Equities research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.